Tampi RR, Tampi DJ, Young JJ, Balachandran S, Hoq RA, Manikkara G. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. World J Psychiatr 2019; 9(3): 47-54 [PMID: 31211112 DOI: 10.5498/wjp.v9.i3.47]
Corresponding Author of This Article
Rajesh R Tampi, MD, Chairman, Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Cleveland, Ohio, NH 44106, United States. rajesh.tampi@gmail.com
Research Domain of This Article
Psychiatry
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Psychiatr. Jun 10, 2019; 9(3): 47-54 Published online Jun 10, 2019. doi: 10.5498/wjp.v9.i3.47
Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
Rajesh R Tampi, Deena J Tampi, Juan J Young, Silpa Balachandran, Rakin A Hoq, Geetha Manikkara
Rajesh R Tampi, Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Ohio, NH 44106, United States
Rajesh R Tampi, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Ohio, Cleveland 44195, United States
Deena J Tampi, Diamond Healthcare, Richmond, VA 23219, United States
Juan J Young, Silpa Balachandran, Case Western Reserve University School of Medicine, Department of Psychiatry, Cleveland, OH 44109, United States
Rakin A Hoq, Department of Psychiatry, Summa Health System, Akron, OH 44304, United States
Geetha Manikkara, Department of Psychiatry, Texas Tech University Health Science Center, Midland, TX 79701, United States
Author contributions: Author contributions: The author contributed equally to this work.
Conflict-of-interest statement: The authors of this study have no conflicts of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Rajesh R Tampi, MD, Chairman, Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Cleveland, Ohio, NH 44106, United States. rajesh.tampi@gmail.com
Telephone: +1-330-3446992 Fax: +1-330-3442943
Received: February 14, 2019 Peer-review started: February 14, 2019 First decision: March 8, 2019 Revised: April 23, 2019 Accepted: May 11, 2019 Article in press: May 11, 2019 Published online: June 10, 2019 Processing time: 115 Days and 23.9 Hours
Abstract
The aim of this editorial is to evaluate the evidence for using pimavanserin for the treatment of Parkinson's disease psychosis (PDP) from randomized controlled trials (RCTs). We only identified two published trials that evaluated the use of pimavanserin among individuals with PDP. Both studies found that pimavanserin improved psychotic symptoms among individuals with PDP when compared to placebo. Pimavanserin was fairly well tolerated in both studies and did not appear to cause significant sedation or worsen motor symptoms among individuals with PDP. However, given the limited data, additional confirmatory studies are required before pimavanserin can be considered as a first line agent for the treatment of psychotic symptoms among individuals with PD.
Core tip: Pimavanserin is an atypical antipsychotic that was the first medication to be approved by the Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). There are only two published trials that have evaluated the use of pimavanserin among individuals with PDP. Both studies are of good quality and found that pimavanserin improves psychotic symptoms among individuals with PDP when compared to placebo. Additionally, pimavanserin was fairly well tolerated in both studies and did not appear to cause significant sedation or worsen motor symptoms among individuals with PDP.
